With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. As part of a new bid ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other ...

Operating Margin Target: 30% by 2027. Net Savings Target: $700 million by 2027. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported its ninth consecutive quarter of growth, with revenue up 5% ...

Q1 adjusted EPS was $0.52, beating $0.48 estimates; Teva raised 2025 EPS outlook to $2.45–$2.65. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for ...

Shares of Teva Pharmaceutical (NYSE:TEVA) traded higher in the premarket on Wednesday after the generic drugmaker cited unfavorable forex movements as its revenue for the first quarter of 2025 ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other ...

Operating Margin Target: 30% by 2027. Net Savings Target: $700 million by 2027. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported its ninth consecutive quarter of growth, with revenue up 5% to ...

Three biosimilar BLAs from Teva-Alvotech are under FDA review, with approvals expected in Q4 2025. Don’t miss this list of 10 overlooked stocks—including one paying a 9% dividend—before Wall ...

Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's target of $0.48. The company missed on sales, however, reporting $3.89 billion for the quarter when $4 ...

JERUSALEM (Reuters) - Teva Pharmaceutical Industries reported a larger than expected rise in first-quarter profit, helped by strong sales gains for a trio of its branded drugs treating migraines ...

Teva reported Q1 earnings, beating Wall Street's EPS expectations. The company raised its full-year guidance as margins expand. Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly ...